Pure Global AI
NCT06032728Not yet recruiting

Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment

A Multi-site, Open, Perspective Study of Prognostic Value and Benefit From Adjuvant Targeted Therapy of Stage III Clear Cell Renal Cell Carcinoma Based on Multimodal Recurrence Scoring System
First Affiliated Hospital, Sun Yat-Sen UniversityClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Renal Cell Carcinoma
Drug/Device/Intervention
Sunitinib
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
First Affiliated Hospital, Sun Yat-Sen University
Timeline & enrollment
Phase
N/A
Start date
Oct 01, 2023
End date
Oct 01, 2033
Enrollment
488 participants
Primary outcome

Disease free survival

Summary

Whether patients with stage III clear cell renal cell carcinoma (ccRCC) should receive
 adjuvant targeted therapy or not is still on debate. The investigators invented a multimodal
 recurrence scoring system that was successfully categorise patients with stage III clear cell
 renal cell carcinoma into high-risk and low-risk groups with Hazard Ratio (HR) of 6.21. Here
 the investigators randomly assign assay-defined high risk patients of locally advanced ccRCC
 into adjuvant targeted therapy group and observation group. Disease free survival and overall
 survival are the end points of observation.

ICD-10 classifications
Malignant neoplasm of kidney, except renal pelvisMalignant neoplasm of renal pelvisSecondary malignant neoplasm of kidney and renal pelvisBenign neoplasm: KidneyBenign neoplasm: Renal pelvis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06032728
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06032728 through Pure Global AI's free database. This phase not specified trial is sponsored by First Affiliated Hospital, Sun Yat-Sen University and is currently Not yet recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 488 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.